

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

2026 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively “**We**”, “**Our**” or “**WuXi AppTec**”) for financial year 2026 (the “**2026 Third Quarterly Report**”). The financial report therein is prepared in accordance with the International Financial Reporting Standards Accounting Standards issued by the International Accounting Standards Board (the “**IFRS Accounting Standards**”) (as applicable) and has not been audited.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 26, 2026

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*

I. Company Profile

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients — one collaboration at a time.

II. The Management's Discussion and Analysis on Operations of the Group for the Reporting Period

Detailed breakdown of our revenue by reportable segments is as follows:

Reportable Segments	First three quarters of 2026 RMB million	First three quarters of 2025 RMB million	Revenue Change (%)
WuXi Chemistry	39,361.7	25,978.1	51.5
WuXi Testing	3,910.9	2,963.4	32.0
WuXi Biology	2,187.8	1,947.3	12.4
Others	77.0	232.7	(66.9)
Subtotal of Continuing Operations	45,537.4	31,121.5	46.3
Discontinued Operations	—	1,735.3	(100.0)
Total	<u>45,537.4</u>	<u>32,856.7</u>	<u>38.6</u>

Note 1: According to IFRS Accounting Standards, the Group has classified the relevant businesses that have signed equity sale agreements, completed sales, or those being discontinued during the Reporting Period or comparative periods, as discontinued operations. Comparative disclosures have been adjusted accordingly.

Note 2: The sum of the data may be inconsistent with the total due to rounding.

In the first three quarters of 2026, total revenue reached RMB45.54 billion, up 38.6% YoY. Revenue from continuing operations increased 46.3% YoY. Backlog for continuing operations reached RMB76.74 billion as of September 30, 2026, up 36.4% YoY.

(1) WuXi Chemistry

Revenue of WuXi Chemistry reached RMB39.36 billion, up 51.5% YoY, mainly driven by steady pipeline progression to late stages, and the sequential ramp-up of new capacity throughout last year. During the first three quarters of 2026:

- CRDMO business model drives continuous growth. We are accelerating proactive capacity planning, and initiated the new Changzhou site ahead of schedule to better meet growing customer demand.
- Small molecule drug discovery (“**R**”, Research) continues to generate downstream opportunities. In the past 12 months, the Company successfully synthesized and delivered more than 450,000 new compounds. 314 molecules were converted from R to D phase during the first three quarters of 2026.
- Small molecule development and manufacturing (“**D**” & “**M**”, Development and Manufacturing) service maintains strong momentum.
 - i. The small molecule CDMO pipeline continued to expand. Driven by ‘follow the molecule’ and ‘win the molecule’, small molecule CRDMO pipeline efficiently converts and captures high-quality molecules, delivering sustained growth. 1,089 new molecules were newly added in the first three quarters of 2026. As of September 30, 2026, our pipeline reached 3,863 molecules, including 103 commercial projects, 94 in phase III, 402 in phase II and 3,264 in phase I and pre-clinical stages. Commercial and phase III projects increased by 23 during the first three quarters of 2026.
 - ii. As our business model continuously attracts high-quality molecules, and the pipeline steadily advances to late stages, aligned with proactive capacity planning and strong execution, revenue of small molecule D&M rose 65.6% YoY to RMB23.58 billion.

- New modalities (TIDES) sustains rapid growth. During the first three quarters of 2026:
 - i. TIDES revenue grew 46.9% YoY to RMB11.52 billion, with full-year revenue expected to grow about 47% YoY.
 - ii. TIDES D&M customers grew 37% YoY, and molecules grew 86% YoY.

(2) WuXi Testing

Revenue of WuXi Testing increased 32.0% YoY to RMB3.91 billion. During the first three quarters of 2026:

- Revenue of drug safety evaluation services grew 40.6% YoY, maintaining its industry-leading position in the Asia-Pacific region.
- The Company is enabling customers' global partnerships to accelerate innovation. New modality business continued its strong momentum, contributing more than 35% of WuXi Testing revenue, while maintaining its leading position in areas including nucleic acids, conjugates, multispecific antibodies and peptides.
- DMPK continues to enhance its science and service capabilities, and accelerate execution of "HI + AI" strategy through integration and automation. With comprehensive enhancement of capacity, quality, and speed, we efficiently fulfill the rapidly growing demand from global AIDD/AI4S customers for dry & wet lab closed-loop R&D, further solidifying our industry leading position.
- Suzhou and Nantong facilities successfully completed their ninth and second consecutive Organization for Economic Co-operation and Development (OECD) GLP periodic inspections, respectively. In addition, Suzhou facility successfully completed its first South Korea Ministry of Food and Drug Safety (MFDS) and three consecutive Japan Pharmaceuticals and Medical Devices Agency (PMDA) project inspections.

(3) *WuXi Biology*

Revenue of WuXi Biology reached RMB2.19 billion, up 12.4% YoY. We enable global customers through integrated *in vitro* & *in vivo* drug discovery capabilities, cross-regional collaboration and end-to-end solutions in emerging areas. During the first three quarters of 2026:

- WuXi Biology follows the science and strategically builds differentiated drug discovery capabilities in emerging areas, actively developing its global business and efficiently generating downstream opportunities for CRDMO model by continuously contributing more than 20% of the Company's new customers.
- We continue to enhance AI and automation capabilities, enabling multiple use cases in pharmacology, pathology, and beyond. In response to the needs of AIDD/AI4S customers, we provide high-throughput, diverse, customized, comprehensive, and integrated wet lab services, fostering novel partnerships with high efficiency and synergy.
- New modality business contributed more than 35% of WuXi Biology revenue, with rapid new customer growth in areas including nucleic acids, antibody conjugates and peptides.

We continue to focus on our unique integrated CRDMO core business, and accelerate global capacity construction and capability development; capture customers' ongoing demand for enabling services, and provide highly efficient and exceptional services, benefiting patients worldwide, and driving long-term growth; and further optimize management and operations, continue to enhance production and operational efficiency, and strengthen resilience to navigate complex and dynamic market conditions.

Driven by greater success of multiple customers' products, our unique CRDMO model, and management and execution excellence, the Company has further raised its full-year guidance for 2026. The Company is targeting 2026 total revenue of RMB61.0–61.9 billion (up from RMB58.5–60.5 billion), with continuing operations revenue now expected to grow 40%–42% YoY (up from 35%–39%). By driving quality growth, realizing scale efficiency and enhancing operational excellence, proactively managing new capacity ramp-up and foreign exchange rate challenges, the Company is confident in maintaining stable and resilient adjusted non-IFRS net profit margin attributable to owners of the Company in 2026. To meet growing customer demand by accelerating global capacity development and initiating the new Changzhou site ahead of schedule, the Company has adjusted 2026 capex forecast to RMB8.0–8.5 billion (from RMB7.5–8.5 billion). Along with business growth and efficiency improvements, 2026 adjusted free cash flow forecast is raised to RMB14.5–15.5 billion (up from RMB13.5–14.5 billion).

The above-mentioned full-year guidance of the Company and its TIDES business for 2026 constitutes forward-looking statements. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks and uncertainties including, but not limited to, the effective competitiveness of our services, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity development plans, our ability to protect our clients' intellectual property, industry competition and regulation, the international geopolitical environment, legislative restrictions and judicial proceedings, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management or an undertaking by the Company to our investors. Accordingly, investors are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All information provided in forward-looking statements is as of the date of this report and is based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information to reflect future events or circumstances, except as required under applicable law.

III. Quarterly Condensed Consolidated Financial Statements Prepared in Accordance with IFRS Accounting Standards

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the nine months ended September 30, 2026

	Continuing Operations		Discontinued Operations		Total	
	Nine months ended		Nine months ended		Nine months ended	
	September 30,		September 30,		September 30,	
	2026	2025	2026	2025	2026	2025
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		(Restated)		(Restated)		
Revenue	45,537,431	31,121,464	—	1,735,253	45,537,431	32,856,717
Cost of sales	(21,156,966)	(16,346,208)	—	(1,391,657)	(21,156,966)	(17,737,865)
Gross profit	24,380,465	14,775,256	—	343,596	24,380,465	15,118,852
Other income	1,002,851	900,355	28,486	19,610	1,031,337	919,965
Other gains and losses	2,707,012	2,547,293	24,045	89,676	2,731,057	2,636,969
Impairment losses under expected credit losses (“ECL”) model, net of reversal	(156,098)	(427,183)	—	(32,404)	(156,098)	(459,587)
Impairment losses of non-financial assets	(27,506)	(149,358)	—	(4,114)	(27,506)	(153,472)
Impairment losses of assets classified as held for sale	—	—	—	(120,737)	—	(120,737)
Selling and marketing expenses	(624,349)	(512,045)	—	(57,330)	(624,349)	(569,375)
Administrative expenses	(2,636,960)	(1,772,632)	—	(196,906)	(2,636,960)	(1,969,538)
R&D expenses	(923,403)	(776,496)	—	(49,155)	(923,403)	(825,651)
Operating profit (loss)	23,722,012	14,585,190	52,531	(7,764)	23,774,543	14,577,426
Share of results of associates	215,617	440,051	—	—	215,617	440,051
Share of results of joint ventures	(177)	635	—	—	(177)	635
Finance costs	(180,342)	(250,187)	—	(7,454)	(180,342)	(257,641)
Profit (loss) before tax	23,757,110	14,775,689	52,531	(15,218)	23,809,641	14,760,471
Income tax expense	(4,545,217)	(2,772,457)	1,149	(58,418)	(4,544,068)	(2,830,875)
Profit (loss) for the period	19,211,893	12,003,232	53,680	(73,636)	19,265,573	11,929,596

	Nine months ended September 30, 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited) (Restated)
Other comprehensive (expense) income for the period		
<i>Items that may be reclassified subsequently to profit or loss:</i>		
Exchange differences arising on translation of financial statements of foreign operations	(1,004,928)	(248,982)
Fair value gain on hedging instrument designated in cash flow hedges	77,617	153,028
Share of other comprehensive expense of an associate, net of related income tax	(8,739)	—
Other comprehensive expense for the period, net of income tax	(936,050)	(95,954)
Total comprehensive income for the period	18,329,523	11,833,642
Profit (loss) for the period attributable to owners of the Company:		
From continuing operations	19,107,405	11,883,809
From discontinued operations	53,680	(81,860)
	19,161,085	11,801,949
Profit for the period attributable to non-controlling interests:		
From continuing operations	104,488	119,423
From discontinued operations	—	8,224
	104,488	127,647
Total comprehensive income for the period attributable to:		
Owners of the Company	18,229,772	11,717,142
Non-controlling interests	99,751	116,500
	18,329,523	11,833,642
Earnings per share (expressed in RMB per Share)		
From continuing and discontinued operations		
— Basic	6.58	4.16
— Diluted	6.47	4.12
From continuing operations		
— Basic	6.56	4.18
— Diluted	6.46	4.15

Condensed Consolidated Statement of Financial Position

As at September 30, 2026

	As at September 30, 2026 <i>RMB'000</i> (Unaudited)	As at December 31, 2025 <i>RMB'000</i> (Audited)
Assets		
Non-current Assets		
Property, plant and equipment	28,757,025	26,233,860
Right-of-use assets	1,790,006	1,629,357
Goodwill	862,147	864,389
Other intangible assets	361,023	414,281
Interests in associates	1,838,195	2,141,502
Interests in joint ventures	3,064	3,375
Deferred tax assets	872,293	531,297
Financial assets at fair value through profit or loss (“FVTPL”)	7,619,998	8,131,208
Other non-current assets	143,532	481,371
Biological assets	1,119,788	1,013,273
Total Non-current Assets	43,367,071	41,443,913
Current Assets		
Inventories	9,977,300	6,922,791
Contract costs	1,626,750	1,101,351
Biological assets	989,328	969,103
Amounts due from related parties	111,734	147,686
Trade and other receivables	12,338,146	9,622,588
Contract assets	644,479	469,518
Income tax recoverable	2,607	8,807
Financial assets at FVTPL	16,343,234	5,806,212
Derivative financial instruments	158,136	68,657
Other current assets	2,462,769	1,402,987
Pledged bank deposits	23,755	12,688
Term deposits with initial term of over three months	7,584,130	5,662,791
Bank balances and cash	29,526,098	29,455,831
	81,788,466	61,651,010
Assets classified as held for sale	—	26,046
Total Current Assets	81,788,466	61,677,056
Total Assets	125,155,537	103,120,969

	As at September 30, 2026 <i>RMB'000</i> (Unaudited)	As at December 31, 2025 <i>RMB'000</i> (Audited)
Liabilities		
Current Liabilities		
Trade and other payables	10,005,010	7,833,267
Amounts due to related parties	2,223	20,364
Derivative financial instruments	5,888	—
Contract liabilities	4,138,494	2,709,160
Bank borrowings	6,185,030	5,986,738
Lease liabilities	147,475	159,018
Income tax payables	3,368,461	2,526,721
Total Current Liabilities	23,852,581	19,235,268
Non-current Liabilities		
Bank borrowings	1,798,500	1,819,100
Deferred tax liabilities	747,902	415,459
Deferred income	908,381	948,171
Lease liabilities	394,175	455,257
Total Non-current Liabilities	3,848,958	3,637,987
Total Liabilities	27,701,539	22,873,255
Capital and Reserves		
Share capital	3,034,904	2,983,757
Reserves	93,810,345	76,728,533
Equity attributable to owners of the Company	96,845,249	79,712,290
Non-controlling interests	608,749	535,424
Total Equity	97,453,998	80,247,714
Total Equity and Liabilities	125,155,537	103,120,969

Condensed Consolidated Statement of Cash Flows

For the nine months ended September 30, 2026

	Nine months ended September 30, 2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Net cash from operating activities	16,608,847	10,872,887
Investing activities		
Interests received	606,533	518,188
Proceeds from disposal of financial assets at FVTPL	14,941,821	6,859,776
Proceeds from partial disposal of associates and a joint venture	3,338,945	3,503,516
Purchases of financial assets at FVTPL	(24,943,670)	(8,635,082)
Purchases of certificates of deposits	(670,940)	—
Purchases of term deposits with initial term of over three months	(6,985,110)	—
Withdrawal of term deposits with initial term of over three months	4,794,129	835,918
Proceeds from disposal of right-of-use assets	107,400	—
Proceeds from disposal of property, plant and equipment	69,621	9,761
Capital injection to an associate	—	(5,601)
Purchases of property, plant and equipment (Placement) withdrawal of rental deposits	(5,041,442)	(3,556,029)
	(2,863)	1,449
Purchases of other intangible assets	—	(540)
Payments for right-of-use assets	(40,364)	(9,748)
Placement of pledged bank deposits	(4,067)	(5,869)
Dividends and distributions received from financial assets at FVTPL	22,322	45,411
Dividends received from an associate	3,480	143,186
Net cash flow from derivative financial instruments	353	(36,444)
Investment awards and other refunds received related to assets	66,736	41,046
Payments of project fees relating to discontinued operations	(2,330)	(106,458)
Net cash inflow on disposal of subsidiaries	428,901	1,343,881
Net cash (used in) from investing activities	(13,310,545)	946,361

	Nine months ended September 30,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Financing activities		
Payments of dividends	(6,232,962)	(4,898,653)
New bank borrowings raised	9,058,514	11,575,750
Repayments of bank borrowings	(8,920,600)	(8,718,797)
Proceeds from the placing of new H Shares	—	6,995,824
Repayments of lease liabilities	(117,522)	(175,463)
Interests paid	(49,782)	(68,148)
Net proceeds from issuance of convertible bonds	6,944,452	—
Acquisition of partial interest of subsidiaries from non-controlling shareholders	—	(61)
Payments on repurchase of A shares and H shares	(3,160,753)	(4,289,244)
Net cash (used in) from financing activities	<u>(2,478,653)</u>	<u>421,208</u>
Net increase in cash and cash equivalents	819,649	12,240,456
Cash and cash equivalents at the beginning of the period	29,455,831	13,444,711
Effects of exchange rate changes	(749,382)	(209,210)
Cash and cash equivalents at the end of the period	<u>29,526,098</u>	<u>25,475,957</u>

IV. Non-IFRS Measures

To supplement our condensed consolidated financial statements presented in accordance with IFRS, we use adjusted non-IFRS gross profit, adjusted non-IFRS net profit attributable to owners of the Company and adjusted free cash flow (collectively the “**adjusted non-IFRS measures**”) as additional financial measures.

The adjusted non-IFRS measures are not an alternative to (i) profit before income tax or profit for the period (as determined in accordance with IFRS) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs, or (iii) any other measures of performance or liquidity.

We believe that the adjusted non-IFRS measures are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our core business.

The management of the Company believes such adjusted non-IFRS measures are widely accepted and adopted in the industry in which the Company operates. However, you should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

1. Adjusted Non-IFRS Gross Profit, Net Profit Attributable to Owners of the Company and Earnings Per Share

	Nine months ended September 30,	
	2026	2025
	<i>RMB million</i>	<i>RMB million</i>
	<i>(except for</i>	<i>(except for</i>
	<i>percentages)</i>	<i>percentages)</i>
	(Unaudited)	(Unaudited)
Net profit attributable to owners of the Company	19,161.1	11,801.9
Add:		
Share-based compensation expenses	851.6	426.3
Issuance expenses of convertible bonds	15.1	28.4
Foreign exchange related losses	805.9	548.0
Amortization of acquired intangible assets from merger and acquisition	15.8	20.5
Gains or losses from divestiture, restructuring and resource integration initiatives	(44.4)	228.3
Non-IFRS net profit attributable to owners of the Company	<u>20,805.1</u>	<u>13,053.5</u>
Add:		
Realized and unrealized gains from venture capital investments	(2,425.7)	(2,515.7)
Realized and unrealized share of losses (gains) from joint ventures	0.2	(0.6)
Adjusted non-IFRS net profit attributable to owners of the Company	<u>18,379.5</u>	<u>10,537.1</u>
Adjusted non-IFRS gross profit <i>(Note 1)</i>	24,940.9	15,455.0
Adjusted non-IFRS gross profit margin:	54.8%	47.0%
WuXi Chemistry	57.1%	51.3%
WuXi Testing <i>(Note 2)</i>	40.8%	29.2%
WuXi Biology	37.4%	37.0%
Adjusted non-IFRS gross profit margin on a constant currency basis	56.5%	47.3%

	Nine months ended September 30,	
	2026	2025
	RMB	RMB
	(Unaudited)	(Unaudited)
Adjusted non-IFRS earnings per share		
— Basic	6.31	3.71
— Diluted	6.21	3.68

Note 1: The adjustments made to the adjusted non-IFRS gross profit mentioned above are the same as those made to the adjusted non-IFRS net profit attributable to owners of the Company at the gross profit level.

Note 2: Adjusted non-IFRS gross profit margin of WuXi Testing refers to continuing operations only, and historical data has been adjusted accordingly.

Note 3: The sum of the data may be inconsistent with the total due to rounding.

2. Adjusted Free Cash Flow

	Nine months ended September 30,	
	2026	2025
	RMB million	RMB million
	(Unaudited)	(Unaudited)
Net cash from operating activities	16,608.8	10,872.9
Add: Income tax expenditures related to significant equity and business sales	671.5	—
Adjusted net cash from operating activities	<u>17,280.3</u>	<u>10,872.9</u>
Less: Capital expenditures	(5,081.8)	(3,566.3)
Adjusted free cash flow	<u>12,198.5</u>	<u>7,306.6</u>

Note: Free cash flow refers to net cash from operating activities less capital expenditures. The adjustments to free cash flow primarily relate to income tax expenditures related to significant transactions, mainly equity or business sales, disclosed in the Company's announcements. Specifically, adjusted free cash flow for the first three quarters of 2026 excludes the impact of tax payments relating to the gain arising from the divestiture of certain business, which was originally recognized in net cash from operating activities. As the gains from the divestiture of certain businesses constitute material non-recurring activities with related proceeds reflected in net cash from investing activities, this adjustment is necessary to ensure an accurate representation of core operating cash flows and to maintain meaningful period-to-period comparability of our financial results.

V. Differences in accounting standards

The differences in net profit and net assets attributable to owners of the Company between the financial reports disclosed under International Financial Reporting Standards (IFRS) and those under Chinese Accounting Standards (CAS) are as follows:

	Net profit attributable to owners of the Company		Net assets attributable to owners of the Company	
			As at	As at
	Nine months ended September 30,		September 30,	December 31,
	2026	2025	2026	2025
	RMB	RMB	RMB	RMB
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
According to CAS	19,398,304,296.86	12,075,512,956.92	96,845,248,979.81	79,712,290,246.44
Items and amounts adjusted according to IFRS:				
Impact of passive dilution of				
equity interest in associates	(237,219,083.30)	(273,564,017.94)	—	—
According to IFRS	19,161,085,213.56	11,801,948,938.98	96,845,248,979.81	79,712,290,246.44

Description of differences in accounting standards:

The differences in accounting standards primarily arise from the different accounting treatments applied to changes in the carrying amount of long-term equity investments resulting from the passive dilution of the Company's equity interest in an associate. In 2023, the Company's equity interest in its associate, WuXi XDC Cayman Inc., was passively diluted following the completion of the associate's public offering. In 2025, the Company's equity interest in the same associate was further passively diluted as a result of the associate's issuance of additional shares. Under CAS, when an investee's equity changes other than net profit or loss, other comprehensive income, and profit distributions, the investor shall adjust the carrying amount of its long-term equity investment, with the corresponding amount recognized in capital reserves. Under IFRS, however, the impact arising from such passive dilution of a long-term equity investment in an associate is recognized in profit or loss for the current period.

During the first three quarters of 2025 and 2026, the Company disposed of part of its equity interest in the associate, resulting in a decrease in its ownership percentage. Under CAS, the related passive dilution impact previously recognized in capital reserves is reclassified to investment income based on the proportion disposed of. Accordingly, differences in accounting standards arose.

VI. Others

The following table sets forth the relevant financial indicators prepared in accordance with the China Accounting Standards for Business Enterprises. For details, please refer to the 2026 Third Quarterly Report of WuXi AppTec Co., Ltd. on the Shanghai Stock Exchange website, dated October 27, 2026.

Items	Nine months ended September 30,	
	2026	2025
	<i>RMB million</i> (Unaudited)	<i>RMB million</i> (Unaudited)
Net profit attributable to owners of the Company	19,398.3	12,075.5
Net profit attributable to owners of the Company after deducting non-recurring gain or loss items	16,476.7	9,522.4

VII. Definitions

“A Share(s)”	domestic shares of our Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“AI4S”	Artificial Intelligence for Science
“AIDD”	Artificial Intelligence-driven Drug Discovery
“Board”	the board of Directors of the Company
“CDMO”	Contract Development and Manufacturing Organization, a CMO that in addition to comprehensive drug manufacturing services, also provides process development, formulation development, clinical trial medications, production of chemically or biologically synthesized active pharmaceutical ingredients, intermediate manufacturing, formulation production (such as powders and injectables), and packaging, as well as customized research and development services for related products
“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only, refers to mainland China

“CRDMO”	Contract Research, Development and Manufacturing Organization
“Director(s)”	the director(s) of the Company or any one of them
“DMPK”	Drug Metabolism and Pharmacokinetics
“end of the Reporting Period”	September 30, 2026
“Group” or “our Group”	the Company and its subsidiaries
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on The Stock Exchange of Hong Kong Limited
“HI”	Human Intelligence
“Reporting Period”	January 2026 to September 2026
“RMB”	Renminbi, the lawful currency of the PRC
“R&D”	research and development
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“Small molecule drug”	small molecule drugs mainly refer to chemically synthesized drugs, typically with a molecular weight of less than 1,000 daltons, with advantages such as wide application and based on well-established theories, currently, the majority of mature drugs on the market are small molecule drugs
“WuXi Chemistry”	chemistry business of the Company
“WuXi Biology”	biology business of the Company
“WuXi Testing”	testing business of the Company
“year-over-year” or “YoY”	for the Reporting Period as compared to the same period in the previous year